For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) closed at $3.52 up 1.73% from its previous closing price of $3.46. In other words, the price has increased by $1.73 from its previous closing price. On the day, 1.07 million shares were traded. MRVI stock price reached its highest trading level at $3.6 during the session, while it also had its lowest trading level at $3.475.
Ratios:
For a deeper understanding of Maravai LifeSciences Holdings Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.56 and its Current Ratio is at 5.29. In the meantime, Its Debt-to-Equity ratio is 1.50 whereas as Long-Term Debt/Eq ratio is at 1.44.
Upgrades & Downgrades
In the most recent recommendation for the company, Robert W. Baird on February 26, 2025, Downgraded its rating to Neutral and sets its target price to $3 from $9 previously.
Goldman Downgraded its Neutral to Sell on December 05, 2024, while the target price for the stock was maintained at $4.25.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 05 ’25 when LUCIER GREGORY T bought 51,472 shares for $3.70 per share. The transaction valued at 190,446 led to the insider holds 106,595 shares of the business.
LUCIER GREGORY T bought 48,528 shares of MRVI for $178,098 on Dec 08 ’25. The Director now owns 155,123 shares after completing the transaction at $3.67 per share. On Nov 13 ’25, another insider, Brust Bernd, who serves as the Chief Executive Officer of the company, bought 216,212 shares for $3.25 each. As a result, the insider paid 702,689 and bolstered with 466,771 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRVI now has a Market Capitalization of 1289696000 and an Enterprise Value of 821263104. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.68 while its Price-to-Book (P/B) ratio in mrq is 2.08. Its current Enterprise Value per Revenue stands at 4.268 whereas that against EBITDA is -10.141.
Stock Price History:
The Beta on a monthly basis for MRVI is 0.33, which has changed by -0.3556797 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, MRVI has reached a high of $6.21, while it has fallen to a 52-week low of $1.66. The 50-Day Moving Average of the stock is 3.61%, while the 200-Day Moving Average is calculated to be 33.52%.
Shares Statistics:
For the past three months, MRVI has traded an average of 1.54M shares per day and 1469830 over the past ten days. A total of 144.72M shares are outstanding, with a floating share count of 105.64M. Insiders hold about 27.16% of the company’s shares, while institutions hold 78.15% stake in the company. Shares short for MRVI as of 1764288000 were 12278685 with a Short Ratio of 7.99, compared to 1761868800 on 12985865. Therefore, it implies a Short% of Shares Outstanding of 12278685 and a Short% of Float of 10.0600004.
Earnings Estimates
A comprehensive evaluation of Maravai LifeSciences Holdings Inc (MRVI) is underway, with the input of 10.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.02 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.29 and -$0.34 for the fiscal current year, implying an average EPS of -$0.31. EPS for the following year is -$0.21, with 11.0 analysts recommending between -$0.15 and -$0.34.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $49.03M this quarter.It ranges from a high estimate of $49.6M to a low estimate of $48.7M. As of. The current estimate, Maravai LifeSciences Holdings Inc’s year-ago sales were $56.56MFor the next quarter, 10 analysts are estimating revenue of $50.6M. There is a high estimate of $65.81M for the next quarter, whereas the lowest estimate is $46M.
A total of 11 analysts have provided revenue estimates for MRVI’s current fiscal year. The highest revenue estimate was $187.7M, while the lowest revenue estimate was $184.62M, resulting in an average revenue estimate of $185.19M. In the same quarter a year ago, actual revenue was $259.19MBased on 10 analysts’ estimates, the company’s revenue will be $202.57M in the next fiscal year. The high estimate is $218.8M and the low estimate is $191.86M.
